OBJECTIVE: To investigate the novel hypothesis that neurotrophin-3 (NT-3), an established neurotrophic factor that participates in embryonic heart development, promotes blood vessel growth. METHODS AND RESULTS: We evaluated the proangiogenic capacity of recombinant NT-3 in vitro and of NT-3 gene transfer in vivo (rat mesenteric angiogenesis assay and mouse normoperfused adductor muscle). Then, we studied whether either transgenic or endogenous NT-3 mediates postischemic neovascularization in a mouse model of limb ischemia. In vitro, NT-3 stimulated endothelial cell survival, proliferation, migration, and network formation on the basement membrane matrix Matrigel. In the mesenteric assay, NT-3 increased the number and size of functional vessels, including vessels covered with mural cells. Consistently, NT-3 overexpression increased muscular capillary and arteriolar densities in either the absence or the presence of ischemia and improved postischemic blood flow recovery in mouse hind limbs. NT-3-induced microvascular responses were accompanied by tropomyosin receptor kinase C (an NT-3 high-affinity receptor) phosphorylation and involved the phosphatidylinositol 3-kinase-Akt kinase-endothelial nitric oxide synthase pathway. Finally, endogenous NT-3 was shown to be essential in native postischemic neovascularization, as demonstrated by using a soluble tropomyosin receptor kinase C receptor domain that neutralizes NT-3. CONCLUSIONS: Our results provide the first insight into the proangiogenic capacity of NT-3 and propose NT-3 as a novel potential agent for the treatment of ischemic disease.
OBJECTIVE: To investigate the novel hypothesis that neurotrophin-3 (NT-3), an established neurotrophic factor that participates in embryonic heart development, promotes blood vessel growth. METHODS AND RESULTS: We evaluated the proangiogenic capacity of recombinant NT-3 in vitro and of NT-3 gene transfer in vivo (rat mesenteric angiogenesis assay and mouse normoperfused adductor muscle). Then, we studied whether either transgenic or endogenous NT-3 mediates postischemic neovascularization in a mouse model of limb ischemia. In vitro, NT-3 stimulated endothelial cell survival, proliferation, migration, and network formation on the basement membrane matrix Matrigel. In the mesenteric assay, NT-3 increased the number and size of functional vessels, including vessels covered with mural cells. Consistently, NT-3 overexpression increased muscular capillary and arteriolar densities in either the absence or the presence of ischemia and improved postischemic blood flow recovery in mouse hind limbs. NT-3-induced microvascular responses were accompanied by tropomyosin receptor kinase C (an NT-3 high-affinity receptor) phosphorylation and involved the phosphatidylinositol 3-kinase-Akt kinase-endothelial nitric oxide synthase pathway. Finally, endogenous NT-3 was shown to be essential in native postischemic neovascularization, as demonstrated by using a soluble tropomyosin receptor kinase C receptor domain that neutralizes NT-3. CONCLUSIONS: Our results provide the first insight into the proangiogenic capacity of NT-3 and propose NT-3 as a novel potential agent for the treatment of ischemic disease.
Authors: Paolo Turrini; Carlo Gaetano; Alessia Antonelli; Maurizio C Capogrossi; Luigi Aloe Journal: Neurosci Lett Date: 2002-04-26 Impact factor: 3.046
Authors: Gianluigi Condorelli; Alessandra Drusco; Giorgio Stassi; Alfonso Bellacosa; Roberta Roncarati; Guido Iaccarino; Matteo A Russo; Yusu Gu; Nancy Dalton; Clarence Chung; Michael V G Latronico; Claudio Napoli; Junichi Sadoshima; Carlo M Croce; John Ross Journal: Proc Natl Acad Sci U S A Date: 2002-09-17 Impact factor: 11.205
Authors: Costanza Emanueli; Maria B Salis; Alessandra Pinna; Gallia Graiani; Luigi Manni; Paolo Madeddu Journal: Circulation Date: 2002-10-22 Impact factor: 29.690
Authors: Oliver A Stone; Christine Richer; Costanza Emanueli; Vincent van Weel; Paul H A Quax; Rajesh Katare; Nicolle Kraenkel; Paola Campagnolo; Luciola S Barcelos; Mauro Siragusa; Graciela B Sala-Newby; Danila Baldessari; Marina Mione; Marie P Vincent; Andrew V Benest; Ayman Al Haj Zen; Julien Gonzalez; David O Bates; Francois Alhenc-Gelas; Paolo Madeddu Journal: Arterioscler Thromb Vasc Biol Date: 2009-01-22 Impact factor: 8.311
Authors: G Graiani; C Emanueli; E Desortes; S Van Linthout; A Pinna; C D Figueroa; L Manni; P Madeddu Journal: Diabetologia Date: 2004-05-26 Impact factor: 10.122
Authors: M J Donovan; M I Lin; P Wiegn; T Ringstedt; R Kraemer; R Hahn; S Wang; C F Ibañez; S Rafii; B L Hempstead Journal: Development Date: 2000-11 Impact factor: 6.868
Authors: Michael DeLay; Arman Jahangiri; W Shawn Carbonell; Yu-Long Hu; Sean Tsao; Maxwell Wing Tom; Jesse Paquette; Taku A Tokuyasu; Manish K Aghi Journal: Clin Cancer Res Date: 2012-04-03 Impact factor: 12.531
Authors: Nicolas Daviaud; Elisa Garbayo; Laurence Sindji; Alberto Martínez-Serrano; Paul C Schiller; Claudia N Montero-Menei Journal: Stem Cells Transl Med Date: 2015-04-29 Impact factor: 6.940
Authors: Ahmed M Abu El-Asrar; Ghulam Mohammad; Gert De Hertogh; Mohd Imtiaz Nawaz; Kathleen Van Den Eynde; Mohammad Mairaj Siddiquei; Sofie Struyf; Ghislain Opdenakker; Karel Geboes Journal: PLoS One Date: 2013-06-07 Impact factor: 3.240